Vinculin is a highly conserved 116-kD protein, which links actin filaments to the cell membrane via cadherins and integrins in cell–cell and cell–matrix adhesion junctions, respectively. It plays a crucial role in brain and heart development, in which it is required for the formation of normal cell–cell and cell–matrix adhesive complexes (
Xu et al., 1998;
Zemljic-Harpf et al., 2007).Vinculin interacts with a large number of proteins (
Ziegler et al., 2006), but most of its binding sites are masked by an intermolecular interaction between the vinculin head and tail domain, which renders the protein inactive (
Bakolitsa et al., 2004;
Borgon et al., 2004). It was proposed that binding of talin to the vinculin head domain and a subsequent helical bundle conversion are sufficient to activate vinculin (
Izard et al., 2004). A combinatorial activation mechanism was also proposed in which vinculin is activated by simultaneous binding of two or more of its ligands (
Bakolitsa et al., 2004;
Janssen et al., 2006). Recent molecular dynamics investigations further support the latter (
Golji and Mofrad, 2010).
The existence of a vinculin splice variant, metavinculin (MV), was recognized nearly three decades ago (
Feramisco et al., 1982). Although extensive research has been performed on vinculin, the function of its larger isoform remains elusive. Vinculin is expressed ubiquitously, whereas MV is mainly expressed in smooth and cardiac muscle tissue (
Feramisco et al., 1982;
Glukhova et al., 1986;
Belkin et al., 1988). A minor fraction of MV can also be found in skeletal muscle tissue and platelets (
Turner and Burridge, 1989). The ratio of the two isoforms depends on tissue type and ranges between 1:1 and 4:1 for vinculin/MV (
Belkin et al., 1988). MV expression appears to be directly correlated to the ability of differentiated muscle cells to contract (
Saga et al., 1985;
Koteliansky et al., 1991), suggesting that MV is important for force transduction.
The sole difference between the two isoforms in humans is a 68-residue acidic insert in MV that is located between residues 915 and 916 of vinculin, a loop between the first two helices (H1 and H2) of the C-terminal tail domain (Vt;
Gimona et al., 1988;
Byrne et al., 1992). In both isoforms, the actin binding site resides in the respective tail domain and is masked by the head domain in the full-length molecule (). Vt forms a five-helix bundle, H1–H5 (
Bakolitsa et al., 1999), with the actin binding site primarily residing in H3, H4, and the C terminus (
Janssen et al., 2006). A helix formed by the C-terminal part of the MV insert (H1′, residues 964–979) replaces H1 in Vt to form a new, but structurally similar, five-helix bundle (
Rangarajan et al., 2010). The ordered “strap” region preceding H1 in Vt is replaced by an equivalent ordered region (residues 947–963) in the MV tail domain (MVt, residues 879–1,134). The residues preceding this region in MVt, MV879–946, are largely disordered in the crystal structures. There is little difference between the head–tail interactions of MV and vinculin. Three mutations are found in the insert region that are associated with dilated and hypertrophic cardiomyopathy: Ala934Val, ΔLeu954, and Arg975Trp (
Olson et al., 2002), exemplifying the functional importance of the insert region.
Here, we compare the influence of Vt and MVt on actin organization. In previous work, we have shown that Vt binds F-actin and mediates the formation of actin bundles (
Janssen et al., 2006). Here, we show that MVt binds and severs actin filaments in a concentration-dependent manner. Unlike Vt, MVt does not bundle actin filaments. 3D reconstructions of actin filaments with bound MVt suggest that the MV879–946 region spatially obscures the vinculin dimerization site, thus preventing higher-order organization of the MVt-bound actin filaments into bundles. These properties of MVt may be essential for modulating compliance of vinculin-induced actin bundles when exposed to rapidly increasing external forces.